Vimarsana
Biggest News Aggregation in the World

Page 9 - John Stover News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from John Stover. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In John Stover Today - Breaking & Trending Today

vasopharm GmbH Announces Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury - Vimarsana News

vasopharm GmbH Announces Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury

/PRNewswire/ -- vasopharm GmbH ("vasopharm"), a privately-held biopharmaceutical company focusing on novel therapeutics to treat cerebrovascular diseases,...

On grief, grandparents and the Mountain Goats [Unscripted] - Vimarsana News

On grief, grandparents and the Mountain Goats [Unscripted]

Grief, and how we deal with it, is a complicated thing.

FreightWaves Classics: U.S. railroads were nationalized in World War I - Vimarsana News

FreightWaves Classics: U.S. railroads were nationalized in World War I

FreightWaves Classics: U.S. railroads were nationalized in World War I An active Pennsylvania Railroad railyard during World War I. (Photo: University of Pennsylvania Archives) and railroads was included. This article expands on the information, presenting an overview of the nationalization of most of America’s railroads during World War I. Railroad problems prior to World War I Interstate Commerce Commission seal. Congress and the Wilson administration had tried to intervene in the railroad industry’s economic struggles for several years. By 1916, there were severe problems withi...

Vasopharm's ronopterin fails in traumatic brain injury trial - Vimarsana News

Vasopharm's ronopterin fails in traumatic brain injury trial

Vasopharm has reported that Phase III trial of ronopterin failed to meet pre-specified primary goal in traumatic brain injury (TBI) patients.

vasopharm GmbH Announces Results of the NOSTRA III Traumatic Brain Injury Phase III Study - Vimarsana News

vasopharm GmbH Announces Results of the NOSTRA III Traumatic Brain Injury Phase III Study

vasopharm GmbH Announces Results of the NOSTRA III Traumatic Brain Injury Phase III Study - Post-hoc analysis reveals clinically meaningful and statistically significant improvement in eGOS when Ronopterin is infused within 12 hours after trauma - But over the entire patient population trial did not meet its primary endpoint - vasopharm will communicate next steps after discussing these results with Competent Authorities - Further results to be published in a peer-reviewed journal - Currently there are no approved treatments for patients with moderate and severe traumatic brain injury News pr...